U.S. Markets close in 4 hrs 24 mins

Ionis Pharmaceuticals’ Valuation on May 23

Mike Benson
Ionis Pharmaceuticals’ Valuation on May 23

Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.